Effectivity of Silymarin in improving hepatic fibrosis among patients with non alcoholic fatty liver disease – placebo controlled RCT
Phase 2
- Conditions
- onalcoholic Fatty Liver Disease
- Registration Number
- SLCTR/2024/011
- Lead Sponsor
- Integrated Health Science Research and Development Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Fatty liver on ultrasonography of the hepatobilliary system -
Hepatocellular steatosis is the hallmark of NAFLD, and steatosis in more than 5% of hepatocytes is required for the diagnosis of NAFLD. Fatty liver is diagnosed based on the following ultrasound parameters; parenchymal brightness, increased echogenicity of the liver parenchyma in comparison to the cortex of the right kidney, deep beam attenuation, bright vessel walls, and gallbladder wall definition.
Exclusion Criteria
1.Alcoholic Fatty Liver Disease
2.Co-infection with HBV
3.Co-infection with HCV
4.Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in Fibroscan score of Liver (Kpa) [After 1(one) year of treatment]<br>Decrease in SGOT (IU/L) [ After 1(one) year of treatment]<br>
- Secondary Outcome Measures
Name Time Method SGOT/SGPT ratio [After 1(one) year of treatment]<br>